January 6, 2017 / 1:13 PM / 7 months ago

BRIEF-Ptc Therapeutics says FDA granted orphan drug designation to RG7916

Jan 6 (Reuters) - Ptc Therapeutics Inc :

* RG7916 granted orphan drug designation in the U.S. For the treatment of spinal muscular atrophy

* PTC Therapeutics Inc says FDA has granted orphan drug designation to RG7916 for treatment of patients with spinal muscular atrophy Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below